Bringing the fundamentals into focus…
Back to Halozyme Therapeutics, Inc.
How Halozyme Therapeutics, Inc. stacks up
HALO · against 588 other Healthcare companies listed in US-listed
Valuation
53/ 100
Above the middle of the pack.
Ranked #163 of 589 · scores higher than 71% of peers
Bars: peers in each 10-point band of the valuation score57 peers with a valuation score of 50–59, including HALO · Click a bar to see the companies
Why valuation scores 53?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- Earnings yield is close to the peer norm. Earnings yield: 2.8% vs peer median 1.5%
- more operating profit (EBITDA) for the company's total value: stronger than 63% of peers. EBITDA yield: 3.7% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 71% of peers. Free cash flow yield: 5.5% vs peer median 0.0%
Metric by metric
Position: dot = HALO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | HALO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | 2.7% | -4.3% | 77% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 6.4% | -0.8% | 76% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 3.6% | -2.3% | 74% | 20% | |
| Book yieldHigher is better · 587 reported | 1.0% | 25.9% | 11% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around HALO| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 163 | 13.8B USD | 53 | 54 | |
| 163 | 161.8B USD | 53 | 50 | |
| 163 | 2.6B USD | 53 | 66 | |
| 163 | 5.5B USD | 53 | 43 | |
| 163 | 14.6B USD | 53 | 59 | |
| 163 | 1.5B USD | 53 | 59 | |
| 163 | 759M USD | 53 | 54 | |
| 163 | 1.6B USD | 53 | 48 | |
| 163 | 258.2B USD | 53 | 47 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score